Targeting KCa3.1 and LRRC8A, along with pathways such as WNK1–AMPK–p38 MAPK and HDAC3, may provide new therapeutic avenues to reeducate and reprogram TAMs within the TME, thereby enhancing the efficacy of cancer immunotherapy. The gene discussed is LRRC8A; the disease is cancer.